Merck & Co. does not anticipate significant effects from the new US tariffs against Canada, Mexico and China, but it is facing a challenge with sales of the human papillomavirus (HPV) vaccine Gardasil, as the company withdrew its 2030 revenue target amid continuing demand issues in China and paused shipments to its commercialization partner there. Meanwhile, Merck expects a $400m impact from the Medicare Part D redesign under the Inflation Reduction Act.
Merck Drops 2030 Sales Target For Gardasil As China Slump Continues
Significant Tariff Impact Is Unlikely
The drug maker withdrew its goal of $11bn in sales for the HPV vaccine and paused shipments to China so that partner Zhifei can reduce its inventory.
